FDA Set to Rule on Regeneron and Roche Drugs
Decisions on Cemdisiran and Gazyva are expected in November 2026, with Giredestrant's review following on November 30.
Updated on Nov. 2, 2026 in Biotech
Live Poll
Do you trust the FDA to approve new treatments safely and on time?
The U.S. Food and Drug Administration has granted Priority Review to Regeneron's Cemdisiran for generalized myasthenia gravis and to Roche's Gazyva for primary membranous nephropathy. Decisions on both drugs are expected in November 2026, and a separate FDA decision on Giredestrant is scheduled for November 30.
Why it matters
Priority Review signals the agency expects significant potential benefit for patients with limited options. The outcomes will shape how Regeneron, Alnylam and Roche compete in treatment markets for rare and chronic autoimmune conditions.
The Nimble trial compared Cemdisiran against placebo, with 76.6% of treated patients reaching a clinically meaningful gain versus 44.1% on placebo. Whether these trial gains will hold across broader patient populations after approval remains unresolved.
The players
Regeneron Pharmaceuticals
Regeneron is a U.S. biotechnology company known for its antibody-based medicines and is developing Cemdisiran under license from Alnylam.
Alnylam Pharmaceuticals
Alnylam is a biotechnology company specializing in RNA interference therapeutics and stands to receive royalties of up to 15% of worldwide Cemdisiran sales.
Roche
Roche is a Swiss pharmaceutical company that develops Gazyva and Giredestrant and reported strong share gains in 2026.
U.S. Food and Drug Administration
The FDA is the U.S. federal agency responsible for reviewing and approving drugs for sale in the United States.
The details
Cemdisiran is administered as an injection once every three months and is being developed by Regeneron under license from Alnylam. Gazyva's MAJESTY trial enrolled 142 patients, and 36.9% of those treated achieved complete remission after two years.
Timeline
June 2026: FDA granted Priority Review to Cemdisiran.
July 2026: FDA granted Priority Review to Gazyva.
November 2026: FDA decisions expected on Cemdisiran and Gazyva.
November 30, 2026: FDA decision scheduled on Giredestrant.
Big Picture
Priority Review under the FDA's expedited review framework accelerates decisions for therapies addressing unmet medical needs, and the Cemdisiran and Gazyva grants place these two candidates within that accelerated track. The pattern suggests biotech pipelines in autoimmune disease are increasingly moving through expedited channels.
Patients with generalized myasthenia gravis or primary membranous nephropathy could gain access to new treatment options if the FDA approves these drugs. Cemdisiran's quarterly injection schedule would reduce dosing frequency compared with more frequent regimens.
The takeaway
Expedited review designations can shorten the path from trial results to patient access, so tracking FDA decisions on these candidates offers a clear view of how quickly new autoimmune therapies may reach the market.
What happens next
FDA decisions on Cemdisiran and Gazyva are expected in November 2026, and a decision on Giredestrant is scheduled for November 30, 2026.
Further reading
Explore more coverage in our Biotech section.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Do you trust the FDA to approve new treatments safely and on time?
